hVIVO plc
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- hVIVO plc (HVO: London, OPORF: OTC) is a full-service contract research organization (CRO) specializing in early-phase clinical development services, including world-leading human challenge trials (HCTs) for infectious and respiratory diseases; end-to-end drug development from preclinical consultancy through Phase III trials; virology and immunology laboratory services under the hLAB brand, encompassing assay development, molecular and cell-based assays, biomarker analysis, and GxP-compliant biobanking/storage via Cryostore; early drug development consulting and biometry services through Venn Life Sciences; and Phase I-III clinical trial execution through CRS clinical units in Mannheim and Kiel, Germany, with approximately 120-bed capacity for first-in-human and proof-of-concept studies. The company maintains a portfolio of HCT models for pathogens and conditions such as RSV, influenza, COVID-19, hMPV, HRV, malaria, asthma, and COPD, supported by quarantine facilities in London (including the flagship Canary Wharf site launched in 2024 with BSL-3 labs), participant recruitment via FluCamp in the UK, and operations across the UK, Germany, Europe, and North America serving big pharma and biotech clients. Founded in 1989 as a spin-out from Queen Mary University of London and formerly known as Open Orphan plc (name changed in October 2022), hVIVO is headquartered at 40 Bank Street, London, England. Recent developments include the 2024 launch of hLAB standalone services and the Canary Wharf facility; the 2025 acquisitions of CRS clinical research units for €10.0 million (adding early clinical capabilities and expected to be earnings accretive in 2026) and Cryostore for long-term sample storage (contributing to diversified revenue and £5.5 million combined H1 2025 revenue); successful delivery of the largest Phase II field trial and key laboratory contracts; and a weighted contracted orderbook of £67 million as of late 2024 stretching into 2026, alongside a strong sales pipeline amid sector headwinds.
Company News
hVIVO names new finance chief to support growth strategy
hVIVO appoints Caroline Shaw to board as Sullivan steps down
hVIVO buys Berlin trials unit for token upfront sum
hVIVO CEO sees strong H2 2026 revenue outlook as development platform expands - ICYMI
hVIVO tipped for upside as order book 'more than doubles'
hVIVO orderbook more than doubles to £65m as revenue shifts to second half
hVIVO win with Decoy Therapeutics signals shift towards broader contract research market, says broker
hVIVO signs consultancy deal with antiviral developer Decoy Therapeutics
hVIVO to host capital markets day as it pitches broader clinical development role
hVIVO sees uptick in human challenge trial demand - ICYMI
hVIVO shares surge as contract wins build investor confidence
Human challenge trials come of age as hVIVO lands world-first whooping cough contract
hVIVO full-year results: Growth strategy and outlook - ICYMI
hVIVO plc (OPORF) Q4 2025 Earnings Call Transcript
Cavendish sees hVIVO's transition year setting platform for recovery as CRO market conditions stabilise
hVIVO targets strong return to growth after transition year
Cavendish maintains buy on hVIVO after influenza trial contract win, sees revenues weighted to 2026
hVIVO shares rise 11% as influenza trial win and rebrand signal integrated strategy bearing fruit
hVIVO inks influenza trial contract and unveils unified brand as integrated platform strategy takes shape
hVIVO surges 50% in two days as ILiAD funding boosts contract hopes